

September 5, 2019



# **Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXR) Featured in NetworkNewsWire Publication Reporting on Momentous Advances in Drug-Delivery Innovation**

NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — [Lexaria Bioscience Corp. \(CSE: LXX\) \(OTCQX: LXR\)](#) today announces its placement in an editorial published by [NetworkNewsWire](#) ("NNW"), a multifaceted financial news and publishing company for private and public entities.

To view the full publication, titled "Innovative Drug-Delivery Systems Benefit Patients and Businesses," visit: <http://nnw.fm/4P2sn>

The search for innovation is vital in any sector but particularly so in health and medicine. While existing products can sometimes be rebranded or improved, the genuinely transformative are focused on saving lives and improving the well-being of patients around the world.

Innovations in bioscience aren't always dramatic. Some, such as gene therapy or new treatments for viruses, can easily grab the headlines. But other improvements can also make a radical difference to people's lives, from making treatments more affordable to making medicines more palatable and efficient, allowing patients to complete courses of treatment. Innovative new delivery systems can achieve these goals and are therefore among the most highly sought-after advances by companies in the fields of medicine, biotechnology and even consumer products.

One important area where this type of innovation has been particularly effective is the delivery of nicotine, in which [Lexaria Bioscience Corp. \(CSE: LXX\) \(OTCQX: LXR\)](#) is making momentous advances.

## **About Lexaria Bioscience Corp.**

Lexaria Bioscience has developed and out-licenses its disruptive delivery technology, which promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria's technology provides increases in intestinal

absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company's website at [www.LexariaBioscience.com](http://www.LexariaBioscience.com).

## **About NetworkNewsWire**

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via [NetworkWire](http://www.NetworkWire.com) to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with [NNW Prime](http://www.NNWPrime.com). As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit <https://www.NetworkNewsWire.com>.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: <http://NNW.fm/Disclaimer>.

## **Forward-Looking Statements**

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

## **Corporate Communications:**

NetworkWire (NW)

New York, New York

[www.NetworkNewsWire.com](http://www.NetworkNewsWire.com)

212.418.1217 Office

[Editor@NetworkWire.com](mailto:Editor@NetworkWire.com)



Source: Lexaria Bioscience Corp.

